Incidence and standardised definitions of mitral valve leaflet adverse events after transcatheter mitral valve repair: the EXPAND study.


Journal

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040

Informations de publication

Date de publication:
03 Dec 2021
Historique:
pubmed: 26 5 2021
medline: 15 12 2021
entrez: 25 5 2021
Statut: epublish

Résumé

An independent panel of experts reviewed all investigator-reported cases of mitral valve leaflet adverse events (LAE) after MitraClip NTR/XTR in the EXPAND study. We aimed to report the findings of the expert panel and standardise definitions for LAE. Standard definitions for different types of LAE were formulated and events adjudicated after detailed review by the expert panel. Enrolling centres reported LAE in 35 cases, 11 leaflet injuries (9 tears, 2 perforations) and 24 single leaflet device attachment (SLDA). The panel confirmed LAE in 20 cases (2.0% incidence), 18 patients had SLDA and 4 had leaflet injury (2 cases had both SLDA and injury). Leaflet injury occurred during device implant and resulted in surgical valve replacement or death. SLDA-alone events were identified during implant (n=2), pre-discharge (n=7) or at 30 days of follow-up (n=7) and were resolved (≤2+ residual MR) with additional clips in 75% of cases. Mitral valve repair with MitraClip NTR/XTR is safe. The rate of LAE is lower than previously reported using older-generation devices. The proposed definitions and findings will help to differentiate leaflet injury from inadequate leaflet insertion and SLDA and provide guidance for consistent diagnosis of LAE post MitraClip implantation.

Sections du résumé

BACKGROUND BACKGROUND
An independent panel of experts reviewed all investigator-reported cases of mitral valve leaflet adverse events (LAE) after MitraClip NTR/XTR in the EXPAND study.
AIMS OBJECTIVE
We aimed to report the findings of the expert panel and standardise definitions for LAE.
METHODS METHODS
Standard definitions for different types of LAE were formulated and events adjudicated after detailed review by the expert panel.
RESULTS RESULTS
Enrolling centres reported LAE in 35 cases, 11 leaflet injuries (9 tears, 2 perforations) and 24 single leaflet device attachment (SLDA). The panel confirmed LAE in 20 cases (2.0% incidence), 18 patients had SLDA and 4 had leaflet injury (2 cases had both SLDA and injury). Leaflet injury occurred during device implant and resulted in surgical valve replacement or death. SLDA-alone events were identified during implant (n=2), pre-discharge (n=7) or at 30 days of follow-up (n=7) and were resolved (≤2+ residual MR) with additional clips in 75% of cases.
CONCLUSIONS CONCLUSIONS
Mitral valve repair with MitraClip NTR/XTR is safe. The rate of LAE is lower than previously reported using older-generation devices. The proposed definitions and findings will help to differentiate leaflet injury from inadequate leaflet insertion and SLDA and provide guidance for consistent diagnosis of LAE post MitraClip implantation.

Identifiants

pubmed: 34031024
pii: EIJ-D-21-00012
doi: 10.4244/EIJ-D-21-00012
pmc: PMC9724852
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e932-e941

Références

JACC Cardiovasc Interv. 2019 Jul 22;12(14):1356-1365
pubmed: 31129091
N Engl J Med. 2018 Dec 13;379(24):2297-2306
pubmed: 30145927
N Engl J Med. 2018 Dec 13;379(24):2307-2318
pubmed: 30280640
J Am Coll Cardiol. 2013 Sep 17;62(12):1052-1061
pubmed: 23747789
N Engl J Med. 2011 Apr 14;364(15):1395-406
pubmed: 21463154
J Am Coll Cardiol. 2009 Aug 18;54(8):686-94
pubmed: 19679246
JACC Cardiovasc Interv. 2016 Sep 26;9(18):e185-6
pubmed: 27592013
J Card Surg. 2015 May;30(5):414-8
pubmed: 25789567
Interv Cardiol Clin. 2019 Oct;8(4):383-391
pubmed: 31445722
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
J Am Coll Cardiol. 2020 May 5;75(17):2236-2270
pubmed: 32068084
Int J Cardiol. 2014 Feb 15;171(3):e113-6
pubmed: 24405839
JACC Cardiovasc Interv. 2010 Feb;3(2):251-2
pubmed: 20170885
Front Cardiovasc Med. 2019 Oct 18;6:146
pubmed: 31681798
J Am Coll Cardiol. 2014 Jun 10;63(22):e57-185
pubmed: 24603191
J Am Coll Cardiol. 2017 Nov 7;70(19):2315-2327
pubmed: 29096801
Eur Heart J Cardiovasc Imaging. 2020 Oct 1;21(10):1131-1143
pubmed: 31605479
JACC Cardiovasc Interv. 2016 Jun 27;9(12):1280-1288
pubmed: 27339846
JACC Case Rep. 2019 Aug 21;1(2):197-201
pubmed: 34316784

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH